Streetbeat News

Products Services

ELDN

Eledon Pharmaceuticals presented updated data on its drug Tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:03 pm

FGEN

FibroGen has received FDA clearance for its investigational new drug FG-3165, a Galectin-9 targeted monoclonal antibody aimed at treating solid tumors.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:02 pm

TDY

Teledyne Brown Engineering, a subsidiary of Teledyne Technologies, has been selected by TerraPower to supply a prototype In-Vessel Transfer Machine for the Natrium Reactor Demonstration Project in Kemmerer, Wyoming. This system will be crucial for refueling operations.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:01 pm

SRRK

Scholar Rock (NASDAQ:SRRK) announced promising data from its Phase 1 DRAGON trial of SRK-181 in combination with pembrolizumab, showing encouraging responses in anti-PD-(L)1 resistant patients across multiple tumor types. The data were presented at the ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:01 pm

JNJ

Johnson & Johnson announced results from a subgroup analysis of the Phase 3 CARTITUDE-4 study, showing that CARVYKTI® significantly improved progression-free survival for patients with high-risk multiple myeloma. The study supported the recent FDA approval of CARVYKTI®.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 7:58 pm

TTWO

Take-Two Interactive Software Inc (NASDAQ:TTWO) is considering selling or closing its Private Division, which includes Intercept Games and Roll7. Both studios are on the verge of shutting down, with most staff already laid off. Efforts to sell the Kerbal Space Program IP have faced challenges, and ongoing projects are uncertain.

Portfolio Pulse from Franca Quarneti

June 03, 2024 | 7:54 pm

MSFT

Microsoft has announced layoffs in its mixed reality division but will continue selling the HoloLens 2 headset. The company remains committed to the Department of Defense's IVAS program and will keep investing in the broader mixed reality hardware ecosystem. Despite the layoffs, Microsoft will support existing HoloLens 2 customers and partners.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 7:52 pm

JNJ

Johnson & Johnson announced positive data from the Phase 3 PERSEUS study, showing that DARZALEX-based regimens significantly improve clinical outcomes in newly diagnosed multiple myeloma patients. The study demonstrated high rates of complete response and sustained minimal residual disease negativity, leading to improved progression-free survival.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 7:51 pm

ATHA

Athira Pharma is set to be issued a US patent for its methods of treating Parkinson's Disease and Lewy Body Disease. This development could enhance the company's intellectual property portfolio and potentially boost its market position in the pharmaceutical industry.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 7:34 pm

SHIBUSD

Shiba Inu (SHIB) has seen a significant increase in its burn rate, with a 1,441.7% spike in the past 24 hours. Traders are bullish, predicting potential price doubling or tripling. Key data points include a rise in transactions and new verified contracts, as well as increased large transactions and active addresses.

Portfolio Pulse from Khyathi Dalal

June 03, 2024 | 7:32 pm